Accounting Changes And Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued expenses Accrued Liabilities Current And Noncurrent Accrued expense Accumulated Deficit During Development Stage [Member] Deficit Accumulated During the Development Stage Additional Paid In Capital Common Stock Additional paid-in capital - common stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Additional Paid In Capital Common Stock [Member] Additional Paid-in Capital Common Stock Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: After Extension [Member] After Extension [Member] After Extension Amendment [Axis] Amendment [Axis] Amendment [Axis] Amendment [Domain] Amendment [Domain] Amendment [Domain] Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Antidilutive securities excluded from computation of earnings per share, amount Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Asset Acquired Other Than Through Business Combination Additional Cash Paid for Existing Inventory Asset Acquired Other Than Through Business Combination Additional Cash Paid For Existing Inventory Asset Purchase Agreement, additional cash payment for existing inventory Asset Acquired Other than Through Business Combination, Cash Paid Asset Acquired Other Than Through Business Combination Cash Paid Asset Purchase Agreement, upfront cash payment Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Baxter Healthcare Corporation Baxter Healthcare Corporation [Member] Baxter Healthcare Corporation Before Extension [Member] Before Extension [Member] Before Extension Black Scholes Option Pricing Model Black Scholes Option Pricing Model [Member] Black Scholes Option Pricing Model Business Description And Basis Of Presentation [Text Block] Business Case One [Member] Case One [Member] Filled positions Case Two [Member] Case Two [Member] Unfilled positions Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Cash And Cash Equivalents Fair Value Disclosure Cash equivalents Cash And Cash Equivalents Period Increase Decrease Net increase (decrease) in cash and cash equivalents Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Supplementary disclosure of noncash investing and financing activities: Cashless Exercise [Member] Cashless Exercise [Member] Cashless Exercise Class Of Stock [Line Items] Class of Stock [Line Items] Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right, Exercised in Period Class Of Warrant Or Right Exercised In Period Warrant exercised Class of Warrant or Right, Exercise Period Class Of Warrant Or Right Exercise Period Warrant exercisable Period Class of Warrant or Right, Fair Value Assumption, Expected Dividend Yield Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield Expected dividend yield Class of Warrant or Right, Fair Value Assumption, Expected Life Class Of Warrant Or Right Fair Value Assumption Expected Life Expected life in years Class of Warrant or Right, Fair Value Assumption, Risk Free Interest Rate Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate Risk-free interest rate Class of Warrant term, steps per year. Class Of Warrant Or Right Fair Value Assumption Steps Per Year Steps Per Year Class of Warrant or Right, Fair Value Assumption, Stock Volatility Class Of Warrant Or Right Fair Value Assumption Stock Volatility Expected volatility Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Class Of Warrant Or Right Outstanding Warrant outstanding Warrants outstanding Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Class of Warrant Term Class Of Warrant Term Warrant term Collaboration Agreement Collaboration Agreement [Member] Collaboration Agreement Collaborative Arrangement Additional Upfront Payment to be Received Collaborative Arrangement Additional Up Front Payment To Be Received Expected Additional milestone payments to be received Commitment And Contingencies [Axis] Commitment And Contingencies [Axis] Commitment And Contingencies [Axis] Commitment And Contingencies [Domain] Commitment And Contingencies [Domain] Commitment And Contingencies [Domain] Commitments And Contingencies Commitments and contingencies (note 8) Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Line Items] Commitments And Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure including description and financial information related to an entity's common stock and stock-based compensation, which may include disclosure of policies, compensation plan details, allocation of stock compensation, incentive distributions, deferred compensation arrangements and share repurchases. Common Stock Disclosure [Text Block] Common Stock Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.001 par value; 250,000,000 shares authorized; 100,725,066 and 100,159,618 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively Consulting fees Consulting Fees Payment for consulting services fee Contingent Consideration By Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Contract Revenue Cost Payments for services Contracts Revenue Research contract revenue Contract Termination, Description Contract Termination Description Contract termination description Contractual Obligation Remaining contractual obligation Conversion Of Stock Amount Converted 1 Exercise of equity-classified warrants to common shares Current Fiscal Year End Date Current Fiscal Year End Date Deferred Rent Credit Deferred rent liability net Deferred Rent Credit Current Deferred rent - current portion Deferred rent-current portion Deferred Rent Credit Noncurrent Deferred rent Deferred rent-non-current portion Deferred Revenue Current Deferred revenue - current portion Deferred Revenue Noncurrent Deferred revenue DEKK Tec Inc D E K K Tec Inc [Member] DEKK Tec Inc Deposits Assets Noncurrent Deposits Depreciation And Amortization Depreciation and amortization Description Of New Accounting Pronouncements Not Yet Adopted Recently Issued Accounting Pronouncements Development Milestone Payments Development Milestone Payments [Member] Development-based milestones Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Stock-Based Compensation Expense on All Employee and Non-Employee Awards Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Net loss per share - basic and diluted Earnings Per Share [Text Block] Net Loss per Share Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Expected recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Unrecognized compensation costs related to unvested restricted stock outstanding Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized compensation costs Employee Stock Option [Member] Employee Stock Option Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity [Member] Equity Estimated Fair Value Of Warrant Estimated Fair Value Of Warrant Estimated fair value of warrant Execution of Subscription Agreement Execution Of Subscription Agreement [Member] Execution Agreement Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Inputs Level 1 [Member] Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Fair Value Inputs Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurement Inputs Disclosure [Text Block] Fair Value Measurements Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurements Recurring [Member] Fair Value, Measurements, Recurring Gain Loss On Sale Of Property Plant Equipment Loss on disposal of fixed assets General And Administrative Expense General and administrative General And Administrative Expense [Member] General and Administrative Expense Group Eight Group Eight [Member] Upon initial clinical study enrollment Group Eleven Group Eleven [Member] Upon two database related milestones Group Five Group Five [Member] Upon the successful U.S. IND application for indibulin Group Four Group Four [Member] Upon receiving a United States Patent for palifosfamide Group One Group One [Member] Upon the filing of an Investigation New Drug application (IND) for darinaparsin Group Seven Group Seven [Member] Upon contract execution Group Six Group Six [Member] Upon a clinical study commencement of enrollment in North America Group Ten Group Ten [Member] Upon the achievement of various milestones Group Three Group Three [Member] Upon enrollment of the first patient in a multi-center pivotal clinical trial Group Two Group Two [Member] Upon the completion of dosing of the last patient for both Phase 1 clinical trials Harmon Hill Ll Harmon Hill Llc [Member] Harmon Hill LLC Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Taxes Paid Cash paid for income taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Deposit Other Assets Deposits Increase Decrease In Operating Assets [Abstract] (Increase) decrease in: Increase Decrease In Operating Capital [Abstract] Change in operating assets and liabilities: Increase Decrease In Operating Liabilities [Abstract] Increase (decrease) in: Increase Decrease In Other Deferred Liability Deferred rent Increase Decrease In Other Noncurrent Assets Other noncurrent assets Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Increase Decrease In Receivables Receivables Intellectual Property Rights Intellectual Property Rights [Member] Intellectual Property Rights Interest Paid Cash paid for interest Intrexon Corporation Intrexon Corporation [Member] Intrexon Corporation Investment Option, Exercise Period Investment Option Exercise Period Option granted, exercisable period J.P. Morgan Securities Inc. [Member] Jp Morgan Securities Inc [Member] J.P. Morgan Securities Inc. Lease Four [Member] Lease Four [Member] The four floor Lease One [Member] Lease One [Member] The first floor Lease Three [Member] Lease Three [Member] The third floor Lease Two [Member] Lease Two [Member] The second floor Legal Entity [Axis] Legal Entity [Axis] Letters Of Credit Outstanding Amount Letter of credit Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Liabilities Liabilities [Member] Liability License Costs Licensing fee Loss Contingencies By Nature Of Contingency [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Domain] Loss Contingency, Nature [Domain] Loss on Sublease Loss On Sublease Loss on sublease M A Boston, MA Maximum [Member] Maximum Milestone Payment Milestone Payment Milestone payment Milestone Payments, Maximum Amount Milestone Payments Maximum Amount Milestone maximum payment Milestone Payment Under License Agreement Milestone Payment Under License Agreement Milestones under the license agreement expense Monthly Payment Monthly Payment [Member] Monthly Payment Nature Of Business [Table] Nature Of Business [Table] Nature Of Business [Table] Nature Of Operations [Line Items] Nature Of Operations [Line Items] Nature Of Operations [Line Items] Net Cash Provided By Used In Financing Activities Continuing Operations Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Cash flows from financing activities: Net Cash Provided By Used In Investing Activities Continuing Operations Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Cash flows from investing activities: Net Cash Provided By Used In Operating Activities Continuing Operations Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Cash flows from operating activities: Net Income Loss Net loss Net loss Net Proceeds From Issuance Of Common Stock Net Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock Non Vested Restricted Stock Non Vested Restricted Stock [Member] Unvested Restricted Common Stock Novella Clinical Inc [Member] Novella Clinical Inc [Member] Novella Clinical, Inc. Number of Products Number Of Products Number of products N Y New York, NY Office Space Under Lease Office Space Under Lease Office space under operating lease Operating Costs And Expenses Total operating expenses Operating Costs And Expenses [Abstract] Operating expenses: Operating Expenses Amounts paid for services incurred Operating Income Loss Loss from operations Operating Lease Additional Office Space Operating Lease Additional Office Space Additional office space under operating lease Operating Leases Expiration Month and Year Operating Leases Expiration Month And Year Operating lease expiration month and year Operating Lease Space Operating Lease Space Operating lease space Operating Leases Rent Expense Net Total rent Expense Operating Leases Rent Expense Sublease Rentals 1 Sublease revenue from subtenant Options To Purchase Common Stock Options To Purchase Common Stock Option to purchase common stock Options Vested [Member] Options Vested [Member] Vested options held by 1 employees Other Additional Capital Additional paid-in capital - warrants issued Other Additional Capital [Member] Additional Paid-in Capital Warrants Other Assets Noncurrent Other non-current assets Other Expenses Other expense Other Liabilities Noncurrent Other long-term liabilities Other Nonoperating Income Expense Other income (expense), net Payments For Repurchase Of Common Stock Payments to employees for repurchase of common stock Payments For Royalties Royalty payment Payments To Acquire Property Plant And Equipment Purchases of property and equipment Percentage of Net Profit Percentage Of Net Profit Percent of company net profit Percentage Of Revenue Percentage Of Revenue Percentage of revenue agreed to pay which is obtained from sublicensor Period Type [Axis] Period Type [Axis] Period Type [Axis] Period Type [Domain] Period Type [Domain] Period Type [Domain] Pharmaceutical Research Associates Inc Pharmaceutical Research Associates Inc [Member] Pharmaceutical Research Associates Inc Phase 1 Phase One [Member] Upon the commencement of Phase 1 clinical trial Phase 3 Phase Three [Member] Phase 3 Phase 2 Phase Two [Member] Upon the dosing of the first patient PPD Development L P P P D Development L P [Member] PPD Development L. P. Preferred Stock [Member] Preferred Stock Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock, $0.001 par value; 30,000,000 shares authorized and no shares issued and outstanding Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Proceeds From License Fees Received Upfront payment received Proceeds From Stock Options Exercised Proceeds from exercise of stock options Proceeds From Warrant Exercises Cash Received Proceeds from exercise of warrants Property Plant And Equipment Net Property and equipment, net Property Subject To Or Available For Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject To Or Available For Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Public Offering Public Offering [Member] Registered direct offering Public offering, net price per share Public Offering Net Price Per Share Issuance & sale of common stock in public offering price per share Quarterly Payment Quarterly Payment [Member] Quarterly Payment Range [Axis] Range [Axis] Range [Member] Range [Domain] Receivables Net Current Receivables Related Party [Domain] Related Party [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions By Related Party [Axis] Related Party [Axis] Related Party Transactions Disclosure [Text Block] Related Party Transactions Requirement Of Eligible Future Milestone Payments [Axis] Requirement Of Eligible Future Milestone Payments [Axis] Requirement Of Eligible Future Milestone Payments [Axis] Requirement Of Eligible Future Milestone Payments [Domain] Requirement Of Eligible Future Milestone Payments [Domain] Requirement Of Eligible Future Milestone Payments [Domain] Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research And Development Arrangement Contract To Perform For Others Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research And Development Expense Research and development, including costs of research contracts Research expenses Research And Development Expense [Member] Research and Development Expense Restricted Stock [Member] Restricted Stock Restructuring Activities Elimination Of Employees [Axis] Restructuring Activities Elimination Of Employees [Axis] Restructuring Activities Elimination Of Employees [Axis] Restructuring Activities Elimination Of Employees [Domain] Restructuring Activities Elimination Of Employees [Domain] Restructuring Activities Elimination Of Employees [Domain] Restructuring And Related Activities [Abstract] Restructuring and Related Activities [Abstract] Restructuring And Related Activities Disclosure [Text Block] Restructuring Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Number of positions eliminated Restructuring Cost And Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Retained Earnings Accumulated Deficit Accumulated deficit Revenue Recognition, Period Revenue Recognition Period Estimated upfront payment for research and development funding earning period Royalty Payments Royalty Payments [Member] Royalty Payments Sale Of Stock Name Of Transaction [Domain] Sale of Stock, Name of Transaction [Domain] Sale Of Stock Price Per Share Sale of stock price per share Sales Events Milestone Sales Events Milestone [Member] Sales-based milestones Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Nonvested Share Activity Table [Text Block] Summary of Unvested Restricted Stock Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Restructuring And Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Schedule of Securities Valuation Assumptions Schedule Of Securities Valuation Assumptions Table [Text Block] Assumptions Used in Binomial and Monte Carlo Valuation Model Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Stock Option Activity Under Stock Option Plan Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders' Equity Note, Warrants and Common Stock Activity Schedule Of Stockholders Equity Note Warrants And Common Stock Activity Table [Text Block] Warrant Exercises Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Number of Warrants Outstanding Security Deposit Security deposits Security Deposit Liability Security deposit from subtenant Segment Geographical [Domain] Geographical [Domain] Severance Costs 1 Total charges incurred related to workforce reduction Share Based Compensation Stock-based compensation Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1 Shares vesting period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Cancelled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Cancelled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Ending Balance Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested [Roll Forward] Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Ending Balance Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value [Roll Forward] Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Vested Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected dividend yield Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1 Expected life in years Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options available for future grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1 Options exercisable, at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Options exercisable, at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Options exercisable, at end of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1 Options exercisable, at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Expected to Vest Number Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Number Shares expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Granted Stock options, granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted-average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Outstanding, at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending Balance Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward] Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending Balance Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Weighted Average Exercise Price Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2 Outstanding, at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Vested and unvested expected to vest at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Vested and unvested expected to vest at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Vested and unvested expected to vest at end of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term 1 Vested and unvested expected to vest at end of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Shares vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted Average Contractual Term (Years) Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Cancelled Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Granted Shares Outstanding Ending Balance (in shares) Beginning Balance (in shares) Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Solasia Pharma K K Solasia Pharma K K [Member] Solasia Southern Research Institute Southern Research Institute [Member] Southern Research Institute Statement Equity Components [Axis] Equity Components [Axis] Statement Geographical [Axis] Geographical [Axis] Statement [Line Items] Statement [Line Items] Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Stockholders Equity Ending Balance Beginning Balance Total stockholders' equity Stockholders Equity [Abstract] Stockholders' equity: Stock Issued During Period Shares New Issues Stock issued during period Stock Issued During Period Shares Restricted Stock Award Forfeited Cancelled restricted stock (in shares) Stock Issued During Period Shares Stock Options Exercised Exercise of employee stock options (in shares) Shares exercised Exercised Number of shares issued during the period as a result of the exercise of warrants. Stock Issued During Period Shares Stock Warrants Exercised Warrant exercise (in shares) Stock Issued During Period Value Restricted Stock Award Forfeitures Cancelled restricted stock Stock Issued During Period Value Stock Options Exercised Exercise of employee stock options Value stock issued during the period as a result of the exercise of warrants. Stock Issued During Period Value Stock Warrants Exercised Warrant exercise Stock Issued Stock Issued [Member] Common Stock Issued Stock Option [Member] Stock Option Stock Repurchased During Period Shares Repurchase of shares of restricted common stock (in shares) Stock Repurchased During Period Value Repurchase of shares of restricted common stock Stock Warrants Text Block Stock Warrants [Text Block] Warrants Subleased Agreement Area Subleased Agreement Area Area under sublease agreement Subsidiary Sale Of Stock [Axis] Subsidiary, Sale of Stock [Axis] Supplemental Cash Flow Information [Abstract] Supplementary disclosure of cash flow information: Term Of Research Collaboration Term Of Research Collaboration Agreement term Text Block [Abstract] Text Block [Abstract] The University Of Texas M D Anderson Cancer Center And The Texas A And M University System The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member] The University of Texas M.D. Anderson Cancer Center and The Texas A & M University System Trading Activity By Type [Axis] Trading Activity [Axis] Trading Activity By Type [Domain] Trading Activity, by Type [Domain] Trading Symbol Trading Symbol Uncategorized [Abstract] Uncategorized [Abstract] Uncategorized [Abstract] Underwriter Underwriter [Member] J. P. Morgan Securities LLC Unrealized Gain Loss On Derivatives Change in fair value of warrants Change in fair value of warrants Up Front Payment Up Front Payment [Member] Up Front Payment Valuation Technique [Axis] Valuation Technique [Axis] Valuation Technique [Domain] Valuation Technique [Domain] Warrant, Cash Exercise Warrant Cash Exercise [Member] Cash exercises Warrant Exercise Price Warrant Exercise Price Exercise price of Warrants decreased Warrant Liabilities, Fair Value Disclosure Warrant Liabilities Fair Value Disclosure Warrant liability Warrant [Member] Warrants Warrants Classified as Equity [Member] Warrants Classified As Equity [Member] Equity Warrants Warrants Issued In Initial Public Offering Warrants Issued In Initial Public Offering Warrants issued Warrants Liability Warrants Liability Warrant liabilities Warrants To Purchase Aggregate Shares Of Common Stock Warrants To Purchase Aggregate Shares Of Common Stock Warrants to purchase an aggregate of shares of common stock Weighted Average Number Of Share Outstanding Basic And Diluted Weighted average common shares outstanding to compute net loss per share - basic and diluted